secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-283108
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology CFO Robert Lapetina resigns; Jim DeTore named interim CFO effective Nov 17, 2025
--------------------------------------------------------------------------------

- Robert Lapetina resigned as interim principal financial and accounting officer, effective Nov 30, 2025.
- Jim DeTore appointed interim principal financial and accounting officer, effective Nov 17, 2025, via consulting agreement with Monomoy Advisors.
- DeTore to receive $32K for November (prorated) and $64K/month thereafter; initial term min 3 months, extendable 3 months.
- DeTore previously CFO at Neurogastrx (2021-2025) and Bluebird Bio (2014-2016); independent consultant 2017-2021.
- No family relationships or conflicts disclosed; DeTore eligible for standard indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000119312525283108/0001193125-25-283108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000119312525283108/ck0001991792-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-283108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer